Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

The trial will begin enrolling US participants early next year, with topline data expected in the second half of the year.

The lift is based on new research showing that the previous adverse effects in laboratory rats may not have been caused by ...

Rezolute (NASDAQ:RZLT) shares gained 13% Monday morning as the U.S. FDA lifted its partial clinical hold on the firm's ...

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Rezolute (RZLT – Research Report), retaining the price target of $7.00.

Rezolute (RZLT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from ...

Rare disease biotech Rezolute recently announced that the FDA has lifted the partial clinical hold on RZ358 (ersodetug), a novel therapy in development for the treatment of low blood sugar ...

For more information on ersodetug and our programs in congenital HI and tumor HI ... 2), thereby improving hypoglycemia in the setting of hyperinsulinism. Because ersodetug acts downstream ...

the ability of RZ358 to become an effective treatment for congenital hyperinsulinism, the effectiveness or future effectiveness of RZ358 to become an effective treatment for congenital ...

The FDA concluded that the liver toxicity observed was likely specific to a particular type of rats called Sprague Dawley, ...

(Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed t Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism ...